Literature DB >> 17117522

Decitabine.

Steven D Gore, Carole Jones, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17117522     DOI： 10.1038/nrd2180

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  35 in total

1.  DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine.

Authors:  Jia Yu; Bo Qin; Ann M Moyer; Somaira Nowsheen; Tongzheng Liu; Sisi Qin; Yongxian Zhuang; Duan Liu; Shijia W Lu; Krishna R Kalari; Daniel W Visscher; John A Copland; Sarah A McLaughlin; Alvaro Moreno-Aspitia; Donald W Northfelt; Richard J Gray; Zhenkun Lou; Vera J Suman; Richard Weinshilboum; Judy C Boughey; Matthew P Goetz; Liewei Wang
Journal:  J Clin Invest       Date:  2018-04-30       Impact factor: 14.808

2.  The case for open-access chemical biology. A strategy for pre-competitive medicinal chemistry to promote drug discovery.

Authors:  Johan Weigelt
Journal:  EMBO Rep       Date:  2009-09       Impact factor: 8.807

Review 3.  Drugging the pain epigenome.

Authors:  Ellen Niederberger; Eduard Resch; Michael J Parnham; Gerd Geisslinger
Journal:  Nat Rev Neurol       Date:  2017-05-26       Impact factor: 42.937

Review 4.  DNA methylation profiles in cancer diagnosis and therapeutics.

Authors:  Yunbao Pan; Guohong Liu; Fuling Zhou; Bojin Su; Yirong Li
Journal:  Clin Exp Med       Date:  2017-07-27       Impact factor: 3.984

5.  Low-dose decitabine for refractory prolonged isolated thrombocytopenia after HCT: a randomized multicenter trial.

Authors:  Yaqiong Tang; Jia Chen; Qifa Liu; Tiantian Chu; Tingting Pan; Jianying Liang; Xue Feng He; Feng Chen; Ting Yang; Xiao Ma; Xiaojin Wu; Shaoyan Hu; Xingyu Cao; Xiaohui Hu; Jiong Hu; Yuejun Liu; Jiaqian Qi; Yueping Shen; Changgeng Ruan; Yue Han; Depei Wu
Journal:  Blood Adv       Date:  2021-03-09

6.  A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia.

Authors:  Jonathan How; Mark D Minden; Leber Brian; Eric X Chen; Joseph Brandwein; Andre C Schuh; Aaron D Schimmer; Vikas Gupta; Sheila Webster; Tammy Degelder; Patricia Haines; Lee-Anne Stayner; Shauna McGill; Lisa Wang; Richard Piekarz; Tracy Wong; Lillian L Siu; Igor Espinoza-Delgado; Julianne L Holleran; Merrill J Egorin; Karen W L Yee
Journal:  Leuk Lymphoma       Date:  2015-03-30

7.  Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.

Authors:  Isabelle Westerlund; Yao Shi; Konstantinos Toskas; Stuart M Fell; Shuijie Li; Olga Surova; Erik Södersten; Per Kogner; Ulrika Nyman; Susanne Schlisio; Johan Holmberg
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-10       Impact factor: 11.205

8.  An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromes.

Authors:  Jacqueline S Garcia; Nitin Jain; Lucy A Godley
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

9.  LC-MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma.

Authors:  Julianne L Holleran; Julie L Eiseman; Robert A Parise; Shivaani Kummar; Jan H Beumer
Journal:  J Pharm Biomed Anal       Date:  2016-07-18       Impact factor: 3.935

10.  Tackling the methylome: recent methodological advances in genome-wide methylation profiling.

Authors:  Marcos Rh Estécio; Jean-Pierre J Issa
Journal:  Genome Med       Date:  2009-11-16       Impact factor: 11.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.